Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-013093
Filing Date
2020-05-14
Accepted
2020-05-14 16:41:08
Documents
1
Period of Report
2020-05-12

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 10776
  Complete submission text file 0000899243-20-013093.txt   12361
Mailing Address HANNAH RUBINA 11 TEL AVIV L3 6937215
Business Address HANNAH RUBINA 11 TEL AVIV L3 6937215 972-52-873-9833
Israel Biotech Fund I, L.P. (Reporting) CIK: 0001652458 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39279 | Film No.: 20878449

Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Issuer) CIK: 0001797336 (see all company filings)

EIN.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)